You are here

Phase 2 Trial of Elobixibat for NAFLD/NASH Treatment Imminent

Potential to Impact Key NASH Markers

Albireo Pharma, Inc., a clinical-stage orphan pediatric liver-disease company, has received investigational new drug application (IND) clearance from the FDA for elobixibat. The first-in-class, once-daily, orally available ileal bile acid transporter (IBAT) inhibitor is for treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). 

NAFLD, a major cause of liver disease, affects approximately one-quarter of the world’s population. It can progress to NASH––liver inflammation and damage from fat buildup in the liver––which is expected to become the leading cause of liver transplants in the U.S. Currently, there are no approved treatments for the condition.

Key markers in patients with NASH include elevated bile-acid levels, elevated cholesterol, insulin sensitivity, and liver inflammation and fibrosis. Data indicate that IBAT inhibitors may have a positive effect on these. Elobixibat, a novel IBAT inhibitor, has minimal systemic exposure, and may have potential in NASH treatment as monotherapy or combination therapy.

The phase 2 randomized, double-blinded, placebo-controlled, multicenter, clinical trial will assess the efficacy and safety of elobixibat in approximately 46 adults with biopsy-confirmed NASH or a suspected diagnosis of NAFLD/NASH. Patients will receive elobixibat 5 mg once daily for 16 weeks.

The primary endpoint is the assessment of change in low-density lipoprotein (LDL) cholesterol, and secondary endpoints include change in liver fat as seen on imaging, and levels of alanine transaminase and serum bile acids. The study is expected to begin in the second quarter of 2019, with results planned for mid-2020.

Source: Albireo Pharma, April 11, 2019

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
More Than 32% of Patients Responded in Trial
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
Evenity Increases New Bone Formation, Lowers Vertebral Fracture Potential